European Commission Approves VELCADE® as a Frontline Induction Therapy … – EON: Enhanced Online News (press release)
|
European Commission Approves VELCADE® as a Frontline Induction Therapy …
EON: Enhanced Online News (press release) Until now, VELCADE's (bortezomib) indication has been limited to its use, in combination with melphalan and prednisone, in adult patients with multiple myeloma that are previously untreated and ineligible for stem cell transplant, and as a single agent … |
